Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Tranylcypromine + Tretinoin |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tranylcypromine | Parnate | Dl-Tranylcypromine | KDM1A Inhibitor 14 | Parnate (tranylcypromine) is a monoamine oxidase inhibitor (MAOI) that also inhibits Kdm1a (Lsd1), which may lead to inhibition of stem cell growth through epigenetic regulation (PMID: 26748182). |
Tretinoin | Aberel|Aknoten|Avita|Renova|Retin-A|all-trans retinoic acid|Vitamin A Acid|ATRA | Tretinoin is a form of retinoic acid, which binds to retinoic acid receptors and activates downstream signaling, potentially inducing cell differentiation and subsequently, apoptosis (PMID: 11704842). Tretinoin is FDA approved for patients with acute promyelocytic leukemia harboring PML-RARA (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KMT2A - AFF1 | acute myeloid leukemia | predicted - sensitive | Tranylcypromine + Tretinoin | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Parnate (tranylcypromine) resulted in increased sensitivity to Tretinoin treatment in acute myeloid leukemia cells harboring a KMT2A-AFF1 fusion (also known as MLL-AF4), with inhibition of cell growth and CD11b expression in culture (Blood (2012) 120 (21): 1345.). | detail... |
KMT2A - AFF4 | leukemia | predicted - sensitive | Tranylcypromine + Tretinoin | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Parnate (tranylcypromine) resulted in increased sensitivity to Tretinoin treatment in a murine leukemic cell line harboring a KMT2A-AFF4 fusion (also known as MLL-AF5q31), with inhibition of cell growth and CD11b expression in culture (Blood (2012) 120 (21): 1345.). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02273102 | Phase I | Tranylcypromine + Tretinoin | Phase 1 Study of TCP-ATRA for Adult Patients With AML and MDS (TCP-ATRA) | Completed | USA | 0 |